Akeso dosed the first patient in its Phase II study of AK146D1 (a TROP2/Nectin-4 bispecific ADC) given with Ivonescimab (PD-1/VEGF bispecific) for advanced non-small cell cancer. The news is an early clinical milestone that supports ongoing development, but it does not yet provide efficacy or safety results.
Akeso dosed the first patient in its Phase II study of AK146D1 (a TROP2/Nectin-4 bispecific ADC) given with Ivonescimab (PD-1/VEGF bispecific) for advanced non-small cell cancer. The news is an early clinical milestone that supports ongoing development, but it does not yet provide efficacy or safety results.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.25
